Skip to main content
. Author manuscript; available in PMC: 2014 Jun 1.
Published in final edited form as: Anal Biochem. 2013 Mar 5;437(1):77–87. doi: 10.1016/j.ab.2013.02.018

Table 2.

Summary of known efflux inhibitor profile with potential fluorescent probes.

Fluorescent substrate Lasalocid Loxapine Mometasone Nicardipine Pimozide Verapamil






B1 C1 G2 B1 C1 G2 B1 C1 G2 B1 C1 G2 B1 C1 G2 B1 C1 G2
B22461c w 9.1 ± 8.4 3.7 ± 1.0 4.4 ± 3.4 3.2 ± 1.0 1.2 ± 0.9 4.3 ± 2.3 w 11.1 ± 6.4 14.2 ± 4.3 w 12.4 ± 4.9
B7431a 15.6 ± 10.9 10.1 ± 4.4 1.9 ± 1.1 1.6 ± 1.0 6.8 ± 4.8 2.6 ± 1.1 5.2 ± 5.2 9.7 ± 8.2 9.9 ± 6.6 12.3 ± 2.5
B7433a w 15.9 ± 6.3 8.0 ± 1.9 w 2.6 ± 1.1 1.0 ± 0.5 2.1 ± 0.8 0.6 ± 0.3 2.6 ± 2.2 1.0 ± 0.8 9.4 ± 4.6 w W 12.3 ± 7.4 7.2 ± 7.3
B7469a w 4.3 ± 1.4 w w 0.5 ± 0.1 w 2.0 ± 2.0 6.2 ± 6.0 0.7 ± 0.4 7.0 ± 1.9 w w w w
B7487a 6.1 ± 2.3 15.5 ± 5.8 1.2 ± 1.3 1.0 ± 0.7 1.9 ± 2.3 0.6 ± 0.0 w w 7.1 ± 6.2 w
C1430b w w 1.9 ± 1.6 5.4 ± 5.6 5.8 ± 2.8 4.3 ± 5.0 13.0 ± 3.0 7.7 ± 3.2 w w
C2927c w w 0.8 ± 0.2 w 1.1 ± 0.8 0.6 ± 0.4 6.1 ± 1.3 w W 17.9 ± 19.9 15.5 ± 6.7
D14730a 8.3 ± 6.5 12.9 ± 8.0 2.4 ± 1.6 1.4 ± 0.3 4.0 ± 2.1 5.3 ± 2.9 2.4 ± 1.3 1.9 ± 0.7 12.8 ± 1.9 5.8 ± 2.7
D22421a 1.7 ± 0.9 2.5 ± 1.7 0.9 ± 0.6 1.9 ± 1.4 0.6 ± 0.5 2.7 ± 4.1 3.5 ± 2.6 9.4 ± 3.6 1.5 ± 0.4 1.1 ± 0.3
D2390c 9.0 ± 6.2 13.5 ± 2.1 4.2 ± 2.4 9.8 ± 6.0 w w 1.5 ± 0.6 2.5 ± 1.8 w 1.2 ± 0.9 1.0 ± 0.4 w 5.9 ± 1.9 3.7 ± 2.8 6.2 ± 5.3 9.6 ± 4.4
D272a w w 0.7 ± 0.2 2.1 ± 2.5 2.6 ± 3.8 w 3.8 ± 1.5 2.9 ± 0.7 W w 22.1 ± 11.7
D273a w w 0.3 ± 0.1 w 0.8 ± 0.9 w 1.7 ± 0.9 1.4 ± 0.7 W 6.3 ± 7.3 7.1 ± 3.2
D306c 20.1 ± 19.4 3.2 ± 4.6 10.2 ± 9.3 1.4 ± 0.6 3.9 ± 3.2 w 8.0 ± 8.8 w
E34251c w w w 2.7 ± 1.9 w 5.0 ± 1.5 4.0 ± 3.2 w 12.9 ± 9.1 w w
H14700a w w w w 4.1 ± 2.5 3.9 ± 2.2 3.3 ± 2.5 w 10.8 ± 2.9 6.0 ± 2.1 w w
L7595c 15.2 ± 7.5 0.9 ± 0.2 w 1.7 ± 1.0 w 7.1 ± 3.0 8.9 ± 5.7 w
M7510c w w 2.2 ± 1.6 w 2.0 ± 0.7 w 5.8 ± 3.4 w w w
M7514c 6.7 ± 0.1 w 6.6 ± 8.7 3.6 ± 0.9 7.8 ± 1.9 11.9 ± 10.8 7.8 ± 9.3 w 7.1 ± 1.1 11.1 ± 1.5
R634a w 3.6 ± 2.2 w 10.1 ± 5.6 w w w w
R648MPc w w 2.9 ± 2.0 2.2 ± 1.1 0.4 ± 0.2 w 5.3 ± 4.9 2.6 ± 2.3 w
S34854a w w 3.1 ± 2.5 1.2 ± 1.0 2.0 ± 0.6 5.6 ± 6.7 6.9 ± 1.3 w W 23.1 ± 0.3 9.9 ± 0.2
S7575a 9.8 ± 3.1 16.2 ± 4.8 1.6 ± 1.6 1.0 ± 0.8 2.3 ± 1.1 1.4 ± 1.1 7.1 ± 4.5 7.2 ± 2.6 7.1 ± 1.9 15.3 ± 7.5
S7578a w w 0.6 ± 0.3 w 1.8 ± 2.6 8.3 ± 7.0 3.3 ± 0.4 W w w
T3168c 5.1 ± 3.9 w w w 2.6 ± 1.9 7.0 ± 3.6 0.9 ± 0.1 3.7 ± 0.8 2.6 ± 1.5 0.5 ± 0.1 15.6 ± 7.6 5.3 ± 2.6 5.7 ± 4.2 w w
T639c w w 1.1 ± 0.4 3.6 ± 2.3 1.1 ± 0.5 w 4.6 ± 0.4 7.5 ± 2.7 w 16.7 ± 4.0
T669c 7.1 ± 8.2 w 9.4 ± 3.6 w w
V12390c 22.3 ± 2.5 w 3.0 ± 2.6 1.8 ± 1.1 0.6 ± 0.4 1.8 ± 1.4 w w 6.2 ± 0.2 9.2 ± 6.1

Note. B1, ABCB1-overexpressing CCRF-ADR 5000 cells; C1, ABCB1-overexpressing SupT1-Vin cells; G2, ABCG2-overexpressing Ig-MXP3 cells. Values are mean IC50 values ± standard deviations (n ≥ 2). The fluorescent substrate concentrations used were one of the following: a100 nM; b250 nM; c500 nM. A dash (–) indicates a lack of response, and a “w” indicates an apparent inhibitory response that fell outside of the tested concentration range or the established cutoff parameters.